T-cell engagers in mAPMR/mCRPC
Published on 25 October 2026
Dr Dominik Berthold updates ecancer at ESMO 2026 about a new area of potential treatment using bispecific T-cell engagers.
This emerging class of targeted immunotherapies is being investigated for advanced prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC, also known as metastatic androgen pathway modulation-resistant prostate cancer) and neuroendocrine prostate cancer (NEPC).
This information is intended for health care professionals only. The information is not intended for US health care professionals.